

Recro Pharma, Inc.  
Form 8-K  
May 28, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 28, 2015**

**Recro Pharma, Inc.**

**(Exact name of registrant as specified in its charter)**

|   |  |  |
|---|--|--|
| <b>Pennsylvania</b><br><b>(State or other jurisdiction of</b> | <b>001-36329</b><br><b>(Commission</b> | <b>26-1523233</b><br><b>(I.R.S. Employer</b> |
| <b>incorporation or organization)</b>                         | <b>File Number)</b>                    | <b>Identification No.)</b>                   |
| <b>490 Lapp Road, Malvern, Pennsylvania</b>                   |  | <b>19355</b>                                 |

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (484) 395-2470

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On May 28, 2015, Recro Pharma, Inc. (the Company ) issued a press release announcing that Gerri Henwood, President and Chief Executive Officer of the Company, will present at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015. The presentation will be webcast and an archived copy will be available in the Presentations section of the Company s website at <http://recropharma.com>. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

The following exhibit is filed herewith:

99.1 Press release, dated May 28, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Recro Pharma, Inc.

By: /s/ Gerri A. Henwood

*Name: Gerri A. Henwood*

*Title: Chief Executive Officer*

Date: May 28, 2015

**EXHIBIT INDEX**

| Exhibit | No.                               | Document |
|---------|-----------------------------------|----------|
| 99.1    | Press release, dated May 28, 2015 |          |